Compare ABM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | IMNM |
|---|---|---|
| Founded | 1909 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 1994 | 2020 |
| Metric | ABM | IMNM |
|---|---|---|
| Price | $44.83 | $21.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $51.50 | $32.10 |
| AVG Volume (30 Days) | 439.8K | ★ 1.0M |
| Earning Date | 03-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | ★ 102.34 | 7.06 |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $8,745,900,000.00 | $9,041,000.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $1.99 | $11.53 |
| P/E Ratio | $16.90 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $40.00 | $5.15 |
| 52 Week High | $54.90 | $27.65 |
| Indicator | ABM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 43.67 |
| Support Level | $44.37 | $18.98 |
| Resistance Level | $46.61 | $22.57 |
| Average True Range (ATR) | 1.24 | 1.18 |
| MACD | -0.23 | -0.31 |
| Stochastic Oscillator | 42.34 | 15.51 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.